scholarly journals High-Risk Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population: Prevalence, Cardiovascular Event Rates, and Costs

2015 ◽  
Vol 22 (12) ◽  
pp. 1287-1304 ◽  
Author(s):  
Keith L Davis ◽  
Juliana Meyers ◽  
Zhenxiang Zhao ◽  
Patrick L McCollam ◽  
Masahiro Murakami
Keyword(s):  
Cardiovascular Disease ◽  
High Risk ◽  
Cardiovascular Event ◽  
Real World ◽  
Japanese Population ◽  
Atherosclerotic Cardiovascular Disease ◽  
Population Prevalence ◽  
Event Rates

scholarly journals Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data

2019 ◽  
Vol 5 (3) ◽  
pp. 225-232 ◽  
Author(s):  
Maria Lindh ◽  
Jonas Banefelt ◽  
Kathleen M Fox ◽  
Sara Hallberg ◽  
Ming-Hui Tai ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Real World ◽  
Disease Risk ◽  
Population Based ◽  
Moderate Intensity ◽  
Atherosclerotic Cardiovascular Disease ◽  
Inclusion Criteria ◽  
Prevalent Cohort ◽  
Event Rates ◽  
Incident Cohort

Abstract Aims This study aimed to estimate the rate of cardiovascular (CV) events in the real world in patients at high risk of recurrent CV events similar to the FOURIER trial population. Methods and results A retrospective population-based cohort study was conducted using Swedish national registers from 1 July 2001 to 31 December 2015. Patients in the atherosclerotic cardiovascular disease (ASCVD) prevalent cohort met the FOURIER-like inclusion criteria, including treatment with high/moderate-intensity statins, on 1 July 2006. Additionally, two cohorts defined by diagnosis of incident ischaemic stroke (IS) and incident myocardial infarction (MI), meeting the FOURIER-like inclusion criteria were followed from date of diagnosis. Event rates were calculated for the hard major adverse cardiovascular events (MACE) composite: MI, IS, and CV death; and the ASCVD composite: MI, IS, unstable angina, coronary revascularization, and CV death. Approximately half of patients experienced a CV event (ASCVD composite) during follow-up. The MACE composite rates/100 person-years were 6.3, 11.9, and 12.3 in the ASCVD prevalent (n = 54 992), MI incident (n = 45 895), and IS incident (n = 36 134) cohorts, respectively. The ASCVD composite rates/100 person-years were 7.0, 21.7, and 12.9 in the ASCVD prevalent, MI incident, and IS incident cohorts, respectively. The multiple-event MACE composite rates/100 person-years were 8.5 (ASCVD prevalent cohort), 15.4 (MI incident cohort), and 14.4 (IS incident cohort). Conclusion In this real-world setting, CV event rates were high in all studied cohorts. In particular, the MACE composite rates were two to three times higher than in the FOURIER clinical trial, indicating a substantial disease burden despite treatment with moderate or high-intensity statins.

scholarly journals Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies

2019 ◽  
Author(s):  
Patrick R Lawler ◽  
Gynter Kotrri ◽  
Maria Koh ◽  
Shaun G Goodman ◽  
Michael E Farkouh ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Real World ◽  
Coronary Revascularization ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cardiovascular Death ◽  
Atherosclerotic Cardiovascular Disease ◽  
Icosapent Ethyl ◽  
Emerging Therapies ◽  
Event Rates

Abstract Aims Hypertriglyceridaemia in patients with atherosclerotic cardiovascular disease (ASCVD) has been in focus following the REDUCE-IT trial showing benefit with icosapent ethyl. Among individuals with prevalent ASCVD, we sought to quantify the contemporary, real-world risk of ASCVD events associated with hypertriglyceridaemia, as well as estimate icosapent ethyl eligibility and compare trial participants with REDUCE-IT-like individuals in the population. Methods and results We examined data from 2 424 865 adults with lipid panels in the Ontario population. Among those with prevalent ASCVD, we examined adjusted associations between triglyceride (TG) and ASCVD events (first occurrence of myocardial infarction, unstable angina, stroke or transient ischaemic attack, coronary revascularization, or cardiovascular death). The proportion of patients with ASCVD potentially eligible for icosapent ethyl was estimated as those with TG 135–499 mg/dL (1.52–5.63 mmol/L) and low-density lipoprotein cholesterol (LDLc) 41–100 mg/dL (1.06–2.59 mmol/L), similar to the lipid cut-offs in REDUCE-IT, and their demographics and event rates examined. Among 196 717 individuals with ASCVD, median age was 69 years and 30% were female. A total of 24 097 composite ASCVD events occurred over a mean (standard deviation) 2.9 (0.5) years of follow-up. Increasing TG was associated with a graded, progressively higher hazard of ASCVD events. Twenty-five percent (49 886) of individuals with ASCVD had hypertriglyceridaemia and controlled LDLc; these patients were demographically similar to those in REDUCE-IT with comparable event rates. Conclusions Among patients with ASCVD, hypertriglyceridaemia is common, and is associated with higher ASCVD risk across a range of TG. It is possible that as many as one in four patients with ASCVD may be candidates for emerging therapies.

Sign in / Sign up

Export Citation Format

Share Document